Powered by WPeMatico
Powered by WPeMatico
Powered by WPeMatico
Powered by WPeMatico
Seoul: Medical professors in South Korea are preparing to challenge the government’s decision to increase medical school admissions, citing concerns over their constitutional rights. The move comes amid ongoing disruptions to the country’s medical services, triggered by a plan to add 2,000 new medical students next year to alleviate a shortage of doctors.
The Medical Professors Association of Korea is scheduled to file the petition with the Constitutional Court before the April 10 general elections against the government’s plan to raise the number of medical students by 2,000 starting next year from the current 3,058 seats to address a shortage of doctors, Yonhap news agency reported.
The plan has caused a massive walkout by junior doctors since February 20, as well as major disruptions to the country’s medical service.
Also Read:South Korea Doctors’ Strike: President Says Won’t back down over medical reforms
Despite earlier attempts by the professors’ association to challenge the government’s plan through the Seoul Administration Court, their case was dismissed without deliberation. Consequently, they now seek recourse with the Constitutional Court, arguing that the government’s decision infringes upon their autonomy of education and other fundamental rights.
According to an IANS report, “The government’s exercise of authority to raise the admissions by 2,000 violates the basic rights of professors, including their autonomy of education,” a lawyer of the group said.
“Following the dismissal, we cannot expect any redemption of our rights by lower courts so we are entitled to bring the case to the Constitutional Court. We will file the petition before the elections next week,” he added.
In addition to the constitutional appeal, the association plans to seek a court injunction this month, preempting the government’s release of detailed entrance requirements for next year’s college admissions.
Meanwhile, the government is determined to accomplish medical reform, Second Vice Health Minister Park Min-soo said on Friday.
He made the remarks at a government response meeting, a day after President Yoon Suk Yeol met a leader of a group of trainee doctors, Yonhap reported.
“The government is determined to accomplish medical reform in a flexible, inclusive, but unwavering manner that upholds principles,” Park said.
Park also called for trainee doctors to end their walkout and continue talks with the government over medical reform.
Powered by WPeMatico
Cambridge: AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumours who have received prior systemic treatment and have no satisfactory alternative treatment options.
This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.
The first tumour-agnostic approval of a HER2-directed therapy and ADC by the Food and Drug Administration (FDA) was based on results from the subgroup of patients with HER2-positive IHC 3+ tumours in each of the DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02 Phase II trials.
Funda Meric-Bernstam, MD, Chair of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, US, said, “Until the approval of trastuzumab deruxtecan, patients with metastatic HER2-positive solid tumours have had limited treatment options. Based on the clinically meaningful response rates seen across clinical trials, this tumour-agnostic approval means that patients may now be treated with a HER2-directed medicine.”
Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said, “As the first antibody drug conjugate to be granted a tumour-agnostic indication, Enhertu is truly delivering on its potential across metastatic HER2-targetable tumours. This approval also elevates the importance of testing for biomarkers, including HER2, across a broad range of tumours to ensure these patients with advanced cancer who have few options know whether a targeted medicine might be right for them.”
Ken Keller, Global Head of Oncology Business, and President and CEO, Daiichi Sankyo, Inc., said, “This fifth indication in the US is a significant milestone as eligible patients with previously treated metastatic HER2-positive solid tumours may now be treated with Enhertu. The accelerated approval by the FDA for this tumour-agnostic indication is based on the clinically meaningful efficacy seen with Enhertu across numerous types of metastatic cancers.”
In the DESTINY-PanTumor02 Phase II trial, patients with centrally or locally assessed HER2-positive (IHC 3+) solid tumours including either biliary tract, bladder, cervical, endometrial, ovarian, pancreatic or other tumours treated with Enhertu showed a confirmed ORR of 51.4% (95% confidence interval [CI] 41.7-61.0) and a median DoR range of 19.4 months (range 1.3-27.9+ [+ denotes ongoing responses at data cutoff]). In DESTINY-Lung01, patients with centrally confirmed HER2-positive (IHC 3+) non-small cell lung cancer (NSCLC) treated with Enhertu showed a confirmed ORR of 52.9% (95% CI 27.8-77.0) and median DoR range of 6.9 months (range 4.0-11.7+). A confirmed ORR of 46.9% (95% CI 34.3-59.8) and median DoR range of 5.5 months (range 1.3+-9.7+) was seen in patients with centrally confirmed HER2-positive (IHC 3+) colorectal cancer in the DESTINY-CRC02 trial.
The safety of Enhertu was evaluated in 347 patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumours in the DESTINY-Breast01, DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02 trials. The safety profile observed across the trials was consistent with previous clinical trials of Enhertu with no new safety concerns identified.
Based on these results, fam-trastuzumab deruxtecan-nxki (Enhertu) has been included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) as a treatment option for multiple metastatic tumours.
This approval was granted under the FDA’s Real-Time Oncology Review programme after securing Priority Review and Breakthrough Therapy Designation for Enhertu in the US in this setting.
The US regulatory submission was reviewed under Project Orbis, which provides a framework for concurrent submission and review of oncology medicines among participating international partners. As part of Project Orbis, Enhertu is also under regulatory review for the same indication by regulatory authorities in Australia, Brazil and Singapore.
Sales of Enhertu in the US are recognised by Daiichi Sankyo. AstraZeneca reports its share of gross profit margin from Enhertu sales in the US as alliance revenue in the Company’s financial statements.
Further details on the financial arrangements were set out in the March 2019 announcement of the collaboration.
Read also:AstraZeneca Enhertu granted priority review in US for metastatic HER2-positive solid tumours
Powered by WPeMatico
Hyderabad: In a significant development for dental healthcare in Hyderabad, Ocean International Dental Hospital unveiled its newest branch in Madhapur, Hyderabad, on Friday. The inauguration ceremony was graced by the esteemed presence of Chhattisgarh Governor Biswabhushan Hari Chandan.
he state-of-the-art facility promises to provide a wide array of ultra-modern dental services, ranging from invisalign and braces to smile design, root canal treatments, laser whitening veneers, implants, dentures, and a host of other specialized procedures. The hospital boasts advanced diagnostic tools such as CBCT and OPG, along with expertise in orthognathic surgeries, crowns, and bridges.
According to an UNI report, Speaking on the occasion, the governor said, “For any dental problems, proper diagnosis and accurate treatment will be done through AI (artificial intelligence) at Ocean International Dental Hospital. The new facility will enable us to know in advance how the result will be after the treatment.”.
Also Read:Telangana Health Minister launches Mobile Dental Hospital
Dr Prasad Penubakula, Founder and Chairman of Prasad Groups and Chairman of Ocean International Dental Hospital, said, “This is the largest dental hospital in Hyderabad. All types of dental problems will be treated here. Special medical facilities are available here for the dental problems of small children.”.
Our key objective is to make medical services available to people from all walks of life, he said.
“We provide holistic and all-encompassing dental care at affordable prices using the most recent technology and cutting-edge procedures, he added.
Pre-checkup counseling, dental health awareness, and discussions are all part of our dental practice. We assist patients with the diagnosis, care, and prevention of dental problems while maintaining a stress-free atmosphere,” he added.
The company already has dental clinics in Visakhapatnam, Vijayawada, and Hyderabad.
Medical Dialogues team recently reported that Jamia Millia Islamia has created 2 new departments including the Department of Medical Sciences, and the Department of Dental Sciences.
Powered by WPeMatico
New Delhi- The All India Institute of Medical Sciences (AIIMS) is going to conduct the professional examinations of undergraduate, postgraduate and fellowship programs from the month of May to June 2024. Regarding this, the examination section of AIIMS has issued a notice informing about the schedule of payment of the examination fee and issuance of admit card.
The notice said that the candidates who are going to appear in the professional examinations of undergraduate and postgraduate are advised to visit the official website of AIIMS to fill out the examination form and pay the examination fee. However, the examination fee should be paid through Debit/Credit Card/Net Banking only. Meanwhile, there is no registration and online payment of examination fees for the Fellowship programme.
STEPS TO FILL OUT THE EXAMINATION FORM AND PAYING THE EXAMINATION FEE
1 Visit the AIIMS website.
2 Go to the “STUDENT TAB”.
3 Click on the Professional Examination Registration link.
Names of the courses:
1 Second MBBS
2 Final MBBS (Supplementary)
3 B.Sc. (Hons) Nursing Phase – I & IV
4 B.Sc. Nursing (Post Basic) Phase – I & II
5 MD / MS / MDS
6 DM / MCh
Online Registration open for Submission of Examination Fee: 15.04.2024
Registration Closing date: 26.04.2024
ADMIT CARD
The notice further instructs that only those candidates who have paid their examination fee as per the schedule can download the admit card by visiting the AIIMS website under the Student tab for the desired course from April 18, 2024.
STEPS TO DOWNLOADING THE ADMIT CARD
1 Click on the Admit Card link.
2 Enter the Enrolment Number.
3 Enter the date of Birth.
All India Institute of Medical Sciences, also known as AIIMS Delhi, is a globally acclaimed public medical research university and hospital based in New Delhi, India. The AIIMS Act, of 1956 govern the institute and operates autonomously under the Ministry of Health and Family Welfare.
To view the notice, click the link below
Powered by WPeMatico
Tamil Nadu- The Sri Lanka Medical Council (SLMC) has accredited SRM Kattankulathur Dental College and Hospital, Tamil Nadu. This was announced in a recently held council meeting, which was presided over by Dr HDB Herath, Sri Lanka Medical Council’s Registrar.
SRM Kattankulathur Dental College and Hospital is renowned for its comprehensive education in science, engineering, technology, medicine, management, agriculture and law, offering a BDS program consisting of four years of academic study followed by a one-year compulsory internship. The institute was started in 2007 with an annual intake of 100 BDS students pursuing UG/PG courses recognised by the Dental Council of India.
According to the TOI media report, Sri Lanka Medical Council has officially accredited SRM Kattankulathur Dental College and Hospital in Tamil Nadu. This accreditation will help Sri Lankan students to enroll into the five-year Bachelor of Dental Surgery (BDS) program at SRM Kattankulathur Dental College and Hospital.
However, this accreditation will also make SRM Kattankulathur Dental College a viable option for Sri Lankan students willing to pursue a career in dental surgery. Additionally, this accreditation will open up new opportunities for Sri Lankan students who aspire to pursue a career in dental surgery and also it will be of great help to the student to get hands-on experience in dental science.
BDS (Bachelor of Dental Surgery) is a 5-years undergraduate program and the only approved professional dental course in India. Students become doctors after the BDS course. It is a compulsory course for students aspiring to work as dentists at government or private hospitals. BDS mainly focuses on training and introducing students to the dental sciences and surgeries. The 5-year program involves 4 years of classroom education and 1 year of compulsory rotating internship.
Powered by WPeMatico
Bengaluru: Granting interim relief to a student, the Karnataka High Court bench recently held that students holding Overseas Citizens of India (OCI) cards are to be treated on par with Indian citizens while participating in Online counselling for admission to undergraduate medical and dental courses for 2024-2025.
“…we are of the opinion that this submission can be recorded that the OCI cardholders are to be permitted to participate in Online counseling for admission to undergraduate courses in Medical, Dental and Engineering for the Academic Year 2024-2025 for both Government and Private seats, on par with Indian citizens,” the HC bench of Justices Anu Sivaraman and Anant Ramanath Hegde ordered on April 02, 2024.
The HC bench passed this order after the State Government informed the bench that it had no objection considering OCI cardholder students for admission to undergraduate medical, dental and engineering seats in government and private colleges on par with Indian citizens for the academic year 2024-25.
Recording the submission, the bench granted relief to the UK-born petitioner. Filing the plea, the petitioner challenged a January 9, 2024 notification that held that eligibility for OCI/PIO candidates for government seats shall be as per the directions issued by the government.
Also Read: OCI candidates can get admission to only NRI quota seats after taking NEET: MHA
As per the latest media report by the Times of India, the UK-born petitioner has been studying for more than 10 years in Bengaluru and completed his class 10 from Mandua and is currently appearing for II PU examination.
The petitioner highlighted that the central government had earlier issued notifications in 2005 and 2009 conferring certain rights on OCI cardholders, including their rights to appear for All-India Pre-Medical Test and such other tests and be considered for admission on par with Indian citizens.
“The state govt and Karnataka Examinations Authority (KEA) are bound by the law declared by the Supreme Court of India and the law declared and directions issued by the division bench of this high court. Since the Supreme Court has clearly held that those OCI cardholders born before March 4, 2021, are entitled to be treated as Indian citizens, KEA cannot make the eligibility of OCI cardholders for govt seats subject to directions issued by the government,” the petitioner contended.
During the hearing of the case, the government advocate Sri M N Sudev Hegde, who appeared for the State submitted that considering the interim orders passed by the High Court earlier as well as the orders of the Supreme Court in respect of the rights of the OCI cardholders to apply for and be considered for admission in Government as well as Private seats in the previous years, as evidenced by the orders produced along with the writ petition, the Government has no objection to the OCI cardholders being considered for admission to undergraduate courses in Medical, Dental and Engineering for the Academic Year 2024-2025 for both Government and Private seats, on par with Indian citizens.
Taking note of this, the bench opined that OCI cardholders are to be permitted to participate in Online counseling for admission to undergraduate courses in Medical, Dental and Engineering for the Academic Year 2024-2025 for both Government and Private seats, on par with Indian citizens.
Medical Dialogues had reported back in 2021 that issuing a gazette notification, the Ministry of Home Affairs (MHA) had stated that the OCI Cardholders can secure admission to “only NRI (Non-Resident Indian) quota seats” in educational institutions based on all-India entrance tests such as National Eligibility cum Entrance Test.
As per the latest gazette notification, dated 04.03.2021, the OCI cardholders “appearing for the all India entrance tests such as National Eligibility cum Entrance Test, Joint Entrance Examination (Mains), Joint Entrance Examination (Advanced) or such other tests” would be “eligible for admission only against any Non-Resident Indian seat or any supernumerary seat”. This way, the OCI cardholders won’t be eligible for “admission against any seat reserved exclusively for Indian citizens.”
However, the matter came to be challenged before the Supreme Court and issuing an interim relief to the OCI Candidates, the top court bench had allowed them to participate in the general category of NEET Counselling for the academic year of 2021-2022.
Last year, the Court ruled that the Central Government rule of barring the Overseas Citizens of India (OCI) cardholders to apply for general category medical seats will be applied prospectively from the date on which the rule was implemented.
To view the order, click on the link below:
https://medicaldialogues.in/pdf_upload/high-court-of-karnataka-official-web-site-235795.pdf
Powered by WPeMatico